RESUMO
BACKGROUND: In-hospital cardiac arrest (IHCA) continues to be associated with high morbidity and mortality. The objective of this study was to study the association of arterial carbon dioxide tension (PaCO2) on survival to discharge and favorable neurologic outcome in adults with IHCA. METHODS: The study population included 353 adults who underwent resuscitation from 2011 to 2021 for IHCA at an academic tertiary medical center with arterial blood gas testing done within 24 hours of arrest. Outcomes of interest included survival to discharge and favorable neurologic outcome, defined as Glasgow Outcome Score of 4-5. RESULTS: Of the 353 patients studied, PaCO2 classification included: hypocapnia (PaCO2 < 35mmg, n=89), normocapnia (PaCO2 35-45mmHg, n=151), and hypercapnia (PaCO2 > 45mmHg, n=113). Hypercapnic patients were further divided into mild (45mmHg < PaCO2 ≤ 55mmHg, n=62) and moderate/severe hypercapnia (PaCO2 > 55mmHg, n=51). Patients with normocapnia had the highest rates of survival to hospital discharge (52.3% vs 32.6% vs 30.1%, p<0.001) and favorable neurologic outcome (35.8% vs 25.8% vs 17.9%, p=0.005) compared those with hypocapnia and hypercapnia respectively. In multivariable analysis, compared to normocapnia, hypocapnia (OR 2.06, 95%CI 1.15-3.70) and hypercapnia (OR 2.67, 95%CI 1.53-4.66) were both found to be independently associated with higher rates of in-hospital mortality. Compared to normocapnia, while mild hypercapnia (OR 2.53, 95%CI 1.29-4.97) and moderate/severe hypercapnia (OR 2.86, 95%CI 1.35-6.06) were both independently associated with higher in-hospital mortality compared to normocapnia, moderate/severe hypercapnia was also independently associated with lower rates of favorable neurologic outcome (OR 0.28, 95%CI 0.11-0.73), while mild hypercapnia was not. CONCLUSION: In this prospective registry of adults with IHCA, hypercapnia noted within 24 hours after arrest was independently associated with lower rates of survival to discharge and favorable neurologic outcome.
RESUMO
INTRODUCTION: Agranulocytosis from antimicrobial therapy with ceftriaxone is rare. We report a case of agranulocytosis resulting from ceftriaxone noted more than 3 weeks into therapy. CASE PRESENTATION: A 72-year-old woman who was started on ceftriaxone for septic arthritis of the left knee 3 weeks before presentation was admitted to the hospital after being found to be neutropenic on outpatient laboratory analysis. Her absolute neutrophil count on admission was 0/µL. The cause of the agranulocytosis was suspected to be ceftriaxone. The drug was stopped, and she was started on granulocyte colony-stimulating factor with gradual resolution of the neutropenia. DISCUSSION: Serious adverse effects of ceftriaxone therapy, such as agranulocytosis, must be monitored for, especially in patients who are receiving prolonged therapy or high doses. Once this cause of agranulocytosis is identified, ceftriaxone therapy should be stopped; if the patient is febrile, an infectious disease workup should be performed and antibiotics should be started; and granulocyte colony-stimulating factor should be administered with daily monitoring of the absolute neutrophil count.
